As the biotechnology and biopharmaceutical industries prepare for 2027, recent industry forecasts point to renewed growth opportunities, continued funding pressures, and a greater emphasis on specialized talent.
Here’s what the data tells us:
Atradius forecasts 3.2% growth in U.S. pharmaceutical output in 2027, following projected growth of just 0.1% in 2026. This potential recovery could support additional manufacturing activity and demand for technical and quality professionals.
Boston Consulting Group reports that emerging drug modalities account for 57% of the industry’s projected five-year pipeline value. Antibody-based therapies remain a significant driver, while cell and gene therapies continue to present both clinical opportunities and commercialization challenges.
EY reports that biotech companies generated $232 billion in revenue in 2025, while emerging companies continue to face financing constraints. Heading into 2027, organizations will need to balance growth initiatives with disciplined workforce planning.
As companies navigate these industry shifts, access to experienced professionals in research and development, clinical operations, quality assurance, regulatory affairs, and biopharmaceutical manufacturing will be critical.
At Biomedical Search Consultants, we help biotechnology, pharmaceutical, and life sciences organizations secure specialized talent through temporary, temp-to-permanent, and direct-hire staffing solutions.
Whether you’re scaling operations, advancing clinical programs, or preparing for future growth, our team can help you build the workforce to support your objectives.
Planning for 2027? Let’s connect.
Tracy Mason | Biomedical Search Consultants
(781) 890-8824
tmason@biomedicalsearch.com